KRAS and non-small cell lung carcinoma: KRAS mutated NSCLC patients was considered to have low ORR and poor prognosis as a whole when receiving chemotherapy [39–41], thus appropriate selection of chemotherapy regimen is vital to improve the prognosis of those patients.